UBS Group AG Purchases 187,220 Shares of Cellebrite DI Ltd. $CLBT

UBS Group AG lifted its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 99.0% during the 4th quarter, HoldingsChannel reports. The firm owned 376,376 shares of the company’s stock after buying an additional 187,220 shares during the period. UBS Group AG’s holdings in Cellebrite DI were worth $6,786,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. CWM LLC increased its holdings in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after purchasing an additional 720 shares during the period. Advisory Services Network LLC bought a new position in shares of Cellebrite DI in the third quarter worth $40,000. First Horizon Corp increased its holdings in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the period. Vestcor Inc bought a new position in shares of Cellebrite DI in the third quarter worth $70,000. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Cellebrite DI by 114.5% in the third quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock worth $83,000 after purchasing an additional 2,403 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $13.46 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The firm has a fifty day moving average of $13.47 and a 200 day moving average of $15.45. The firm has a market capitalization of $3.36 billion, a PE ratio of 48.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.15.

Insider Transactions at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 13,269 shares of company stock valued at $169,592 in the last ninety days. 5.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and an average target price of $21.75.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.